Hard-nosed Baxter also pragmatic

Baxter Healthcare Corp. last week punted its cell separation technology into a joint venture with VimRx Pharmaceuticals Inc. after vigorously defending the technology against alleged infringement by CellPro Inc.'s Ceprate SC Stem Cell Concentration System.

That Baxter no longer appeared prepared to oversee development of the technology seemed at odds with its interest in pursuing CPRO (Bothell, Wash.) in litigation that started in 1992. In April, after a federal court jury ruled that CPRO had infringed two patents held by Johns Hopkins University covering CD34 monoclonal antibodies and purified stem cells used in CPRO's system, Baxter moved to finish the job. The company, joined by fellow plaintiffs Becton Dickinson and

Read the full 1093 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE